AbbVie jumps 11.5% in a month on strong Q2 results, raised guidance and momentum from Skyrizi, Rinvoq and neuroscience growth.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Priorities change as you enter new seasons of life. That's especially true for your retirement years.
![]() ABBV In 1 month Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 1 month ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 4 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 7 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 10 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
29 Oct 2025 (In 2 months) Date | | 3.26 Cons. EPS | - EPS |
28 Oct 2025 (In 2 months) Date | | 3.22 Cons. EPS | - EPS |
31 Jul 2025 Date | | 2.89 Cons. EPS | - EPS |
23 Jul 2025 Date | | 3.22 Cons. EPS | 2.97 EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
![]() ABBV In 1 month Estimated | Quarterly | $1.64 Per Share |
![]() ABBV 1 month ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 4 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 7 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 10 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
29 Oct 2025 (In 2 months) Date | | 3.26 Cons. EPS | - EPS |
28 Oct 2025 (In 2 months) Date | | 3.22 Cons. EPS | - EPS |
31 Jul 2025 Date | | 2.89 Cons. EPS | - EPS |
23 Jul 2025 Date | | 3.22 Cons. EPS | 2.97 EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | XWBO Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Jul 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.